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after the invasive treatment and the idea of having 
intercourse 3 time a week is often too much for a couple.  
Moreover, again the fear of pain makes both the women and 
her partner reluctant for even trying intercourse. 
In the literature we find that women who have been 
irradiated in the pelvic region express a need for information 
about the consequences of radiation therapy in terms of 
possible vaginal and sexual changes. Others have added that 
interventions aiming at improving (sexual) health have to 
take into account different aspects, e.g.,  the relationship, 
body-image, sexual identity and vaginal changes. Others 
revealed that women and their partners need individually 
tailored information and - practical advice about the side-
effects of the treatment including a focus on sexual 
rehabilitation. 
Based on a qualitative study, Cullen et al. (2013) formulated 
the following eight recommendations for professional 
counseling with women undergoing pelvic radiation therapy :  
  
1. Introduce the dilator in a light and straightforward 
manner 
2. Enhance dilator accessibility 
3. Introduce the vaginal dilator early on in treatment 
4. Emphasize (vaginal) health maintenance over 
intercourse as a benefit of dilator use 
5. Explore and acknowledge women’s values and 
views of sexuality 
6. Increase awareness and sensitivity to emotional 
reactions 
7. Enhance psychological educational resources for 
supporting vaginal dilator use 
8. Ensure consistent institutional practice when 
introducing the dilator 
During my talk, I will describe in more detail how these 
recommendations can be used in daily practice based on my 
experience in the University Hospital of Leuven, Belgium. 
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Purpose/Objective: Lung cancer (LC) has a significant impact 
on patients' health-related quality of life (HRQOL). This study 
aimed to investigate the correlations among patient, tumor, 
and pre-radiation therapy treatment factors and the global 
health status (GHS) and functional scales scores reported by 
LC patients before radiation therapy (RT). In addition, we 
investigated whether the pre-RT HRQOL assessment impacts 
in survival. 
Materials and Methods: We conducted a prospective 
multicentric study with a quality-of-life survey on 171 LC 
patients just before starting radiation treatment. HRQOL was 
assessed using the EORTC-QLQ-C30 (v3.0) questionnaire and 
GHS, physical (PF), role (RF), emotional (EF), cognitive (CF), 
and social functioning (SF) scores were evaluated. Several 
patient factors (age, sex, Karnofsky performance status 
[KPS], weight loss, duration of symptoms before diagnosis, 
living distances from homes to hospitals, respiratory/cardiac 
comorbidities, and smoking habits), tumor features 
(histology, stage), and other treatments before RT (induction 
chemotherapy and surgery) were considered for the analysis. 
Multivariate analyses were performed by using a logistic 
regression model, with a stepwise backward elimination 
procedure. 
Results: The median age at diagnosis was 63 years (range, 
35-89). The TNM classification was as follows: 7 I, 18 II, 129 
III, and 17 IV. The median GHS, PF, RF, EF, CF, and SF scores 
for the entire group of patients were 58%, 73%, 66%, 75%, 
83%, and 83%, respectively. In the multivariate analysis, 
patients losing weight prior to beginning RT reported lower 
GHS scores (OR 0.42; CI: 0.22-0.79; P = 0.007) and PF (OR 
0.41; CI: 0.22-0.76; P = 0.005). In terms of SF, patients 
reporting higher SF scores before treatment had a lower risk 
of mortality (OR 0.20; CI: 0.42-0.95; P = 0.043) and relapse 
(OR 0.30; CI: 0.10-0.88; P = 0.029). In addition, patients with 
non-adenocarcinoma LC reported lower SF (OR 0.31; CI: 0.14-
0.71; P = 0.005). Finally, patients who had induction 
chemotherapy reported higher EF scores (OR 2.00; CI: 1.06-
3.77; P = 0.031).  
Conclusions: Pre-RT HRQOL assessment associates with 
outcome in LC patients. Knowledge of these results may be 
used to assist the radiation oncology team to identify risk 
factors associated with lower HRQOL outcomes before RT and 
enable to make a collaborative multidisciplinary approach 
covering the specific needs for each patient.  
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Purpose/Objective: To evaluate the impact of variation of 
urinary symptoms and incontinence, prospectively evaluated 
by means of 2 validated questionnaires (QSTs), IPSS and ICIQ-
SF (hereafter ICIQ), in the first year after post-prostatectomy 
(PoP) radiotherapy (RT) end, on anxiety and depression 
(ANX/DEP) as measured by HADS (Hospital Anxiety and 
Depression Scale) questionnaire. 
Materials and Methods: In 2012 a prospective, observational, 
single Institute study for the evaluation of urinary toxicity 
from whole-pelvis RT (WPRT) was activated. This analysis 
pertains to the first 113 pts with available baseline (BSL) and 
end-RT IPSS, ICIQ and HADS QSTs. Median age was 66 years, 
median interval from prostatectomy to RT was 3.6 and 45 
months for the 63 and 50 pts treated with adjuvant and 
salvage intent, respectively. RT was delivered with static-
field IMRT, Tomotherapy and VMAT in 19, 54 and 41 pts, 
respectively, at conventional fractionation (CF, 1.8-2 Gy) in 
45 pts, and moderate hypofractionation (HYPO, median 2.35 
Gy/fraction) in 68. WPRT was delivered at 50.4 Gy/28 
fractions in CF, at 52.50 Gy/28 fractions in HYPO. Adjuvant 
androgen deprivation (AAD, median 2 years) was prescribed 
for 32 pts. The prevalence of clinically significant (score ≥8) 
anxiety (ANX≥8) and depression (DEP≥8) before (n=113), 
during (half, n=95), at RT end (n=115) and 3 (n=96), 6 (n=90) 
and 12 (n=72) months after its completion were considered. 
Wilcoxon tests were performed to find significant differences 
